Valeant Pharmaceuticals Receives FDA Complete Response Letter for Latanoprostene Bunod

LAVAL, Quebec, July 22, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news